Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.58 |
| ▸ | PPARA | Q07869 | 9/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107895 | 1.00 | PPARG (0.58) | PPARGPPARADPP4TRPV1FFAR1 | |
| SCHEMBL7107310 | 1.00 | PPARG (0.58) | PPARGPPARADPP4TRPV1FFAR1 | |
| SCHEMBL6486378 | 0.96 | PPARG (0.59) | PPARGPPARADPP4TRPV1SRR | |
| SCHEMBL27561049 | 0.86 | PPARG (0.49) | PPARGPPARADPP4TRPV1FFAR1 | |
| SCHEMBL6500458 | 0.82 | PPARA (0.51) | PPARGPPARAESR1PPARD | |
| SCHEMBL7102284 | 0.82 | PPARA (0.51) | PPARGPPARAESR1PPARD | |
| SCHEMBL7102287 | 0.82 | PPARA (0.51) | PPARGPPARAESR1PPARD | |
| SCHEMBL5607507 | 0.81 | PPARA (0.57) | PPARGPPARAESR1PPARD | |
| SCHEMBL1840733 | 0.81 | SIGMAR1 (0.57) | DPP4FFAR1ESR1SIGMAR1 | |
| SCHEMBL7103261 | 0.81 | PPARA (0.57) | PPARGPPARAESR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| US-20030008361-A1 | Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids | EBDRUP SOREN (DK) | 2003-01-09 | — | — | US | disclosed |
| EP-1254101-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| CN-1375013-A | Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids | NOVO NORDISK AS (DK) | 2002-10-16 | — | — | CN | disclosed |
| EP-1206565-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 3-PHENYL-PROPANOIC ACID ESTERS AND SUBSTITUTED 3-PHENYL-PROPANOIC ACIDS | NOVO NORDISK A/S (DK) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001011073-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 3-PHENYL-PROPANOIC ACID ESTERS AND SUBSTITUTED 3-PHENYL-PROPANOIC ACIDS | NOVO NORDISK A/S (DK) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885DPP4 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.